复星医药小分子创新药XH-S004实现海外权益许可,潜在总额达6.45亿美元

智通财经
Aug 11, 2025

8月11日,复星医药发布公告,控股子公司上海复星医药产业发展有限公司(“复星医药产业”)与Expedition Therapeutics, Inc.("Expedition")签订《许可协议》,将向Expedition授予小分子口服二肽基肽酶1(DPP-1)抑制剂XH-S004在全球(不包括中国境内及港澳地区)范围的开发、生产及商业化权利。复星医药产业将保留XH-S004在中国境内及港澳地区的开发、生产及商业化权利。

根据协议,Expedition将向复星医药产业支付至多1.2亿美元不可退还的首付款、开发里程碑付款,未来还将基于XH-S004于许可区域的年度净销售额的达成情况,由Expedition依约支付至多5.25亿美元的销售里程碑款项。

XH-S004为复星医药产业拥有自主知识产权的小分子口服DPP-1抑制剂,其通过抑制DPP-1及其激活的中性粒细胞丝氨酸蛋白酶降低炎症反应,从而阻断感染恶性循环及由此导致的气道结构损伤;截至目前,XH-S004用于治疗非囊性纤维化支气管扩张症于中国境内处于II期临床试验阶段、用于治疗慢性阻塞性肺疾病(COPD)于中国境内处于Ib期临床试验阶段。截至目前,全球范围内尚无同一分子机制的小分子口服抑制剂获批上市。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10